Corcept Therapeutics (NASDAQ:CORT) Insider William Guyer Sells 20,000 Shares

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider William Guyer sold 20,000 shares of the business’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $35.18, for a total transaction of $703,600.00. Following the transaction, the insider owned 1,235 shares in the company, valued at approximately $43,447.30. This trade represents a 94.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

William Guyer also recently made the following trade(s):

• On Tuesday, December 2nd, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $80.08, for a total value of $1,601,600.00.
• On Tuesday, November 25th, William Guyer sold 4,500 shares of Corcept Therapeutics stock. The shares were sold at an average price of $80.90, for a total value of $364,050.00.
• On Wednesday, November 5th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $75.36, for a total value of $1,507,200.00.

Corcept Therapeutics Price Performance

Shares of NASDAQ CORT traded down $0.47 during trading on Thursday, hitting $36.53. 1,863,444 shares of the company were exchanged, compared to its average volume of 2,714,316. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.14 and a quick ratio of 3.07. Corcept Therapeutics Incorporated has a 1 year low of $32.99 and a 1 year high of $117.33. The firm’s fifty day moving average price is $73.57 and its 200 day moving average price is $73.80. The company has a market cap of $3.84 billion, a price-to-earnings ratio of 41.51 and a beta of 0.23.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.02). The company had revenue of $207.64 million for the quarter, compared to analyst estimates of $223.78 million. Corcept Therapeutics had a return on equity of 15.99% and a net margin of 14.19%.The company’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.41 earnings per share. On average, sell-side analysts expect that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Pathstone Holdings LLC lifted its position in Corcept Therapeutics by 0.8% in the 3rd quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock valued at $1,497,000 after purchasing an additional 144 shares during the last quarter. Huntington National Bank increased its stake in shares of Corcept Therapeutics by 54.0% in the second quarter. Huntington National Bank now owns 479 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 168 shares during the period. Focus Partners Wealth raised its holdings in shares of Corcept Therapeutics by 0.5% during the first quarter. Focus Partners Wealth now owns 33,243 shares of the biotechnology company’s stock valued at $3,797,000 after buying an additional 170 shares during the last quarter. Campbell Newman Asset Management Inc. boosted its position in shares of Corcept Therapeutics by 0.5% during the third quarter. Campbell Newman Asset Management Inc. now owns 35,530 shares of the biotechnology company’s stock worth $2,953,000 after buying an additional 170 shares during the period. Finally, Nisa Investment Advisors LLC grew its holdings in Corcept Therapeutics by 1.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 9,951 shares of the biotechnology company’s stock worth $730,000 after buying an additional 180 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. UBS Group started coverage on shares of Corcept Therapeutics in a report on Tuesday, December 16th. They set a “neutral” rating and a $95.00 target price for the company. Wall Street Zen downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, October 18th. Truist Financial set a $50.00 target price on Corcept Therapeutics in a report on Wednesday, December 31st. HC Wainwright decreased their price target on shares of Corcept Therapeutics from $145.00 to $90.00 and set a “buy” rating on the stock in a research note on Friday, January 2nd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Corcept Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $80.83.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.